Hematology/Oncology 

John Sealy

Research & Clinical TrialsHematology/Oncology


The Division of Hematology/Oncology current research activities are focused on quality improvement, outcomes and comparable effectiveness. Our integrated practice brings together a multispecialty cancer treatment team of experts to ensure you get the best care available. Together, we are dedicated to advancing medical knowledge through basic science and applied clinical science and sharing our discoveries for the benefit of society.

 

What is a Clinical Trial?

A Clinical trial is a scientific research study that is intended to discover better ways to treat or prevent diseases. The studies are performed on humans and regulated by the Food and Drug Administration (FDA).

Physicians use clinical trials to understand the effectiveness and safety of new treatments in patients. Such studies are important in the development of new treatments for diseases.

All clinical trials are voluntary. Participants always have the choice whether or not to take part in a clinical trial. The patient has the right to leave a clinical trial at any time, for any reason. If the patient does decides to leave, the health care team may ask that the participant to continue to be monitored for a period of time to look for any long-term effects of treatment.

More information about Clinical Trials can be found at Clinical Trials website.

What happens during a clinical trial?

The clinical trial process depends on the kind of trial being conducted. The clinical trial team includes doctors and nurses as well as social workers and other health care professionals. They check the health of the participant at the beginning of the trial, give specific instructions for participating in the trial, monitor the participant carefully during the trial, and stay in touch after the trial is completed.

Who can participate in a clinical trial?

All clinical trials have guidelines about who can participate. The criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. Please ask your physician to see if you may qualify for a clinical trial.

How can I get involved in a clinical trial?

Consult with your treating physician regarding current clinical trials and the benefits for you.

MEDICAL ONCOLOGY CLINICAL TRIALS


MYELODYSPLASTIC SYNDROMS (MDS) and ACUTE MYELOID LEUKEMIA (AML) REGISTRY

  • Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

ANEMIA

  • IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose injection).

BREAST CANCER

  • EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
  • S1416 Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
  • A011502 A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

GASTROINTESTINAL & GANITOURINARY CANCERS

  • A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
  • S1500 A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
  • NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
  • NRG-GU002 PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL

HEAD AND NECK CANCERS

  • EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS EFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

LUNG

  • LUN15-233Randomizsed Phase II Trial of Docetaxel plus Novolumab and Docetaxel alon in patients with advanced non-squamous NSCLC previously treated with single agent Nivolumab
  • Phase 1b/II Trial of Carfilzomib with Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Subjects (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy (Onyx IST Reference Number: CAR-IST-553)

For more information contact: 
Nakia Watson
Phone: 409.772.1973
Email: Nakia Watson